The in vitro metabolism of a widespread natural product, trachyloban-19-oic acid (1), by the fungal species Mucor plumbeus was studied in a sucrose-yeast liquid medium. Two products were isolated, and their structures were determined by spectroscopic means as 7β-hydroxytrachyloban-19-oic acid (5) and trachyloban-19-O-β-D-glucopyranosyl ester (6). To the best of our knowledge, compound 6 is herein reported by the first time in the literature. These compounds were assayed for acetylcholinesterase inhibition along with some related compounds. Compound 6 showed the highest acetylcholinesterase inhibitory activity at 10000 µg/mL among the tested compounds, a result (92.89%) comparable to the activity of the positive control, galanthamine (94.21%). Therefore, biotransformation of the natural product 1 by M. plumbeus produced a novel compound with potential as a new lead to develop anti-Alzheimer medicines.
INTRODUCTION
Pharmaceutical interest on synthesis of new natural products derivatives has increased due to multiple bioactivities related to these compounds (Alvin et al. 2014) . A modern synthetic strategy for producing new natural products consists on biotransformation, due to its capacity to introduce functional groups in different positions of carbon skeleton, thus improving pharmacological properties of target compounds (Yang et al. 2015) . In fungi, there is a large variety of enzymes, which have been proved to be useful for biocatalytic processes, catalyzing many chemical reactions, including oxidations, hydroxylations, and reductions among others (Baydoun et al. 2016) . Besides, this methodology presents regio-and stereo-selectivity due to the chiral nature of enzymes and can be accomplished at room temperature, under neutral aqueous conditions. Biotransformations carried out with whole cells have yet the advantages of no need of expensive cofactors. Therefore, enzymatic reactions conducted by fungi have been a promise for a greener organic chemistry, thus contributing to a growing advance in the development of new drugs from compounds of natural origin (Hollmann et al. 2011 , Xu et al. 2016 
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Mucor species are known as an important bioresource, bearing rich enzyme systems and fast growth. Fungi from Mucor genus usually do not produce mycotoxins and are thermotolerant, making them one of the first choice species to be employed in biotechnological processes (Nunes et al. 2013 , Silva et al. 2014 . Mucor species are able to make chemical modifications in the skeleton of structurally diverse natural products such as terpenes (Chen et al. 2015) , steroids (Donova and Egorova 2012), coumarins (Lv et al. 2012) , among other (Silva et al. 2014 ).
Alzheimer's disease is a degenerative neurological disorder which has becoming a very concerning problem in contemporary world. Inhibition of acetylcholinesterase (AChE) enzyme by drugs as galanthamine is currently the most established approach to treat Alzheimer's disease (Najaf et al. 2017) . Search for new acetylcholinesterase inhibitors, equally effective but less expensive than galanthamine is pursuit worldwide. Widespread natural products like diterpenes from trachylobane class have been isolated in high yields from plants commonly present in several countries. Their ready availability and cosmopolite distribution makes them potential sources of novel drugs. In this context, we report herein the preparation and evaluation of trachyloban-19-oic acid (1) derivatives as acetylcholinesterase inhibitors. Dried fruits of Xylopia sericea were extracted from hexane. During the extraction, a solid material precipitated and removed by filtration. This material was solubilized and recrystallized from methanol/ acetone (3:2). After 48 hours, a solid precipitated and was filtered off, dried and analyzed by 1 H and 13 C NMR spectroscopy and melting point, being characterized as trachyloban-19-oic acid (1, 1075 mg). A minor component was obtained from recrystallization of the remaining hexane extract and identified as 15β-hydroxy-trachyloban-19-oic acid (2, 88.5 mg) (Table I) . Methyl trachyloban-19-oate (3) was prepared from iodomethane (62% yield) (Boeck et al. 2005) . Compound 1 was subjected to reduction from LiAlH 4 to furnish trachyloban-19-ol (4) (34% yield). Compounds 2-4 were identified by 1 H and 13 C NMR spectroscopy and melting points and are in accordance with data reported in the literature (Takahashi et al. 2001 ).
MATERIALS AND METHODS

GENERAL EXPERIMENTAL PROCEDURES
BIOTRANSFORMATION EXPERIMENT
M. plumbeus was transferred to Petri dishes containing PDA and allowed to grow for 7 days at room temperature. After full growth, spores were harvested and used for liquid medium inoculation. Forty-eight flasks containing liquid medium were used for biotransformation experiment (Rocha et al. 2010) . Liquid medium was prepared using sucrose 
RESULTS AND DISCUSSIONS
Trachyloban-19-oic acid (1) showed moderate AChE inhibitory activity (52.33 ± 4.10%) (Table II) while its natural derivative 2 was significantly more active (88.36 ± 4.19%) which was an indicative that presence of a hydroxyl group in the molecule may be related to an improved AChE inhibition by this class of compounds. Conversion of carboxylic acid at C-19 of compound 1 into its alcohol derivative 4 caused a huge drop in activity (30.99 ± 4.38%) showing that a carboxyl group at C-19 has also positive effect over acetylcholinesterase inhibition. This was proven by preparing the ester derivative 3. Its activity was slight higher (60.39 ± 4.76%) than activity of trachyloban-19-oic acid (1) ( Table  II) . Therefore, there were indicatives that presence of both a carboxyl group at C-19 in the skeleton is important for AChE inhibition.
Since biotransformations are a choice tool to insert hydroxyl groups in terpenes (Aleu et al. 1999 , Barrero et al. 1999 , Takahashi et al. 2014 , compound 1 was fed to M. plumbeus aiming at obtaining hydroxylated trachylobane derivatives for biological screening as AChE inhibitors. After nine days of biotransformation, TLC profile of the resulting organic extract showed presence of biotransformation products, both of them more polar than starting material 1. The extract was subjected to silica gel column chromatography allowing isolation of products 5 and 6 (Figure 1) . Their structures were determined by NMR experiments.
Both products showed a double triplet at δ 0.57 ppm, typical of H-12 present in the cyclopropane ring of the starting material skeleton (Vasconselos et al. 2015) . Structure elucidation of the products was accomplished after careful analysis of 1 H and 13 C NMR spectra and by correlations found in HSQC, COSY, NOESY and HMBC spectra (Table   I ). There were also used data from high resolution mass spectrum (HRMS) and infrared. 
TABLE I (continuation)
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IDENTIFICATION OF COMPOUNDS OBTAINED BY BIOTRANSFORMATION
Product 5 was obtained as a white amorphous solid. 13 C NMR spectrum of 5 showed lack of a chemical shift assignable to C-7 (39.2 ppm in the starting material) while a new signal was detected at 75.0 ppm (carbinolic carbon), suggesting hydroxylation at C-7 position. 7α-hydroxylated trachyloban-19-oic acid (ciliaric acid) is a compound already described in the literature (Fraga 1994); however, 13 C NMR chemical shift reported for C-7 of ciliaric acid did not match the value found for C-7 of product 5 (both spectra recorded in pyridine-d 5 ). Therefore, derivative 5 should possess β-stereochemistry at C-7. NOESY correlations found for 5 showed spatial proximity of hydrogen H-7 with H-6, H-14 and H-15. Since both hydrogen atoms at C-14 are in the alpha face of the molecule, spatial correlation between H-7 and H-14 is only possible for an α-hydrogen atom in C-7. Therefore, the hydroxyl group is indeed located in β position. This correlation confirms the assignment of this product structure as 7β-hydroxytrachyloban-19-oic acid (5), previously reported by Silva et al. (2002) . Hydroxylation of non-activated methylene carbons is one of the most useful biotransformations (Faber 2011), usually performed by hydroxylases from Cytochrome P450 mono-oxygenases complex system (Montellano 2005). Metabolite 6 was obtained as a white amorphous solid (25 mg).
13
C NMR spectrum revealed that all carbon signals of 1 were present, along which six new carbinolic carbon signals. Chemical shift of the carboxyl group at C-19 showed a significant alteration (δ 184.5 to 175.4 ppm), suggesting an esterification at C-19 by a hexose in the structure of 6. HMBC correlations showed J 3 correlation of the anomeric hydrogen with C-19. Multiplicity of H-1' (J = 8.2 Hz) indicated that this hydrogen should be in axial position (Shimoda et al. 2006 ).
Comparison of 13 C NMR data to the literature indicated that the hexose present in the structure of 6 should be a β-D-glucopyranosyl group (Hu et al. 2012) . Therefore, structure of 6 was determined as trachyloban-19-O-β-D-glucopyranosyl ester. This compound is reported herein by the first time to the best of our knowledge. Complete NMR assignment for compounds 1, 5 and 6 can be found in Table I . In biological processes, glycosylation reactions catalyzed by glycosyltransferases are accomplished in three fundamental steps: activation, transfer and modification. Then, glycosyltransferase enzymes transfer a saccharide moiety from an activated nucleotide sugar molecule to a nucleophilic acceptor (Faber 2011 , Huang et al. 2015 . Glycosylation as a biocatalytic process is important because it can greatly influence the biological activity of natural products, increasing both chemical and biological stability of the compound (Overwin et al. 2015) .
The activity for acetylcholinesterase inhibition of biotransformation products 5 and 6 was measured (Table II) . As expected, compound 5 was very active (51.95 ± 1.93%), since this compound bears two groups important for activity, a carboxyl group at C-19 and also, a hydroxyl group, like compound 2. Glycosylation in C-19 was the most significant structural modification leading to the highest activity (92.89 ± 0.18%) among the tested compounds, a level of inhibition comparable to Galanthamine, the positive control used in the bioassay (94.21 ± 0.20) .
AChE inhibition of trachyloban-19-oic acid (1) and biotransformation products 5 and 6 was analyzed in four concentrations, ranging from 10 to 0.625 mg/mL (Figure 2) .
The original natural product (1) was the least active compound. Conversion of 1 into 5 by biotransformation significantly affected AChE inhibition, since 5, nevertheless as active as the precursor 1, was active up to the concentration of 1250 µg/mL, although still less active than galantamine. On the other hand, glycosylated biotransformation product 6 was active up to the concentration of 625 µg/mL, being as active (92.89%) as galanthamine (94.21%) at the concentration of 10000 µg/mL, but also active in lower concentrations. AChE inhibitory activity of biotransformation products 5 and 6 was dose dependent implying that these derivatives should possess selective action on acetylcholine inhibition.
In conclusion, biotransformation of the natural product trachyloban-19-oic acid showed to be a good tool to produce new activated compounds of trachylobane diterpenes class. Trachyloban-19-O-β-D-glucopyranosyl ester (6), obtained as the major biotransformation product, was highly active for inhibition of AChE, an enzyme directly targeted in the treatment of Alzheimer's disease. Presence of the 19-O-(β-D-glucopyranosyl) group in trachylobanoic acid skeleton increased acetylocholinesterase inhibitory activity, while starting material trachyloban-19-oic acid (1) was moderately active. The report of AChE inhibitory activity for this class of compounds is very relevant since trachylobane diterpenes can be isolated in high amounts from nature (Hernández et al. 2012 ) being a straightforward source of starting material for industrial new drugs development. Therefore, drugs from this class arise as potential greener and cheaper alternatives for the development of anti-Alzheimer medicines to replace available medicines currently used in therapeutics.
